KRAS and colorectal carcinoma: A number of retrospective analyses have revealed that patients with KRAS mutations do not benefit from cetuximab treatment, suggesting that KRAS genotype is a useful predictive marker for cetuximab therapy in CRC (Karapetis et al, 2008; Bokemeyer et al, 2009; Van Cutsem et al, 2009).